Ideas
KOSPI likely rebounds if US stable.
Foreign investors lifted KOSPI futures late in the session; if the US market does not fall sharply overnight, the Korean market may rebound to some extent the next day, but this is a short-term tactical setup dependent on US stability.
Rotation into food and cosmetics emerging.
With the Dow outperforming and Korean food/cosmetic names such as Korea Kolmar, Samyang Foods and Binggrae showing firm price action, the speaker sees early signs that global asset allocation may be rotating away from growth and semiconductor-led areas into previously ignored domestic staples; he frames this as a regime to monitor rather than a direct recommendation.
Samsung and SK Hynix dips buyable.
Samsung Electronics, SK Hynix and Samsung Electronics preferred remain buy-on-dip candidates; valuations and supply are supportive, and today's pullback is a buying opportunity for investors who do not own them, though the speaker warns against making them an extreme half-of-portfolio concentration.
KOSDAQ strength favors ETF exposure.
If KOSDAQ stays stronger than KOSPI through September 6, the speaker expects KOSDAQ strength could accelerate into year-end or the first half next year; ETF inflows into KOSDAQ names, policy support and a prior supply vacuum support interest, but he recommends ETF-based exposure over individual stock risk and would consider raising his KOSDAQ allocation from 35 percent to 40 percent only if it holds up.
ESS shortage makes Korean battery makers attractive.
Korean secondary battery names are very positive because ESS is becoming tied to AI data centers and national security; US restrictions on Chinese components may create shortages by 2027, benefiting Korean companies with US factories and vertical integration, while Tesla's recovery, EV momentum and oil volatility add demand; the speaker sees Samsung SDI as the leader and also flags LG Energy Solution, SK On, L&F and POSCO Future M as names to check, focusing on Samsung SDI and material and component names.
Hanmi Pharm has obesity and licensing drivers.
Hanmi Pharm is one of the few Korean pharma and biotech companies generating profits alongside Samsung Biologics and Celltrion; today's large licensing-out deal, expected second-half obesity drug sales and upcoming clinical data around year-end or October make it worth checking, with the key being how much revenue and operating profit the obesity drugs contribute.
US biotech strength may lift Korean pharma.
The US biotech index is showing better price action than the S&P 500, and the speaker believes Korean pharma and biotech may follow the strength; because individual names are hard to analyze and can gap on clinical news, he suggests ETF-based access to the Korean biotech and pharma complex.
Semiconductors still lead; lower tiers attractive.
Semiconductors are still the leading sector, and the speaker sees lower-tier semiconductor stocks as attractive for further upside; however, the main index trend support needs to hold because a break would indicate supply rather than valuation, so investors should confirm the support zone rather than chase blindly.
This 3PRO TV (삼프로TV) video, published August 24, 2026,
features Lee Jae-kyu
discussing EWY, 161890.KS, 003230.KS, 005180.KS, 005930.KS, 005935.KS, 000660.KS, KOSDAQ Index, KOSDAQ, 006400.KS, 066970.KS, 003670.KS, 128940.KS, XBI, Korean biotech/pharma ETF, Korean semiconductor sector, Korean semiconductor materials/equipment.
8 trade ideas extracted by AI with direction and confidence scoring.
Speakers:
Lee Jae-kyu
· Tickers:
EWY,
161890.KS,
003230.KS,
005180.KS,
005930.KS,
005935.KS,
000660.KS,
KOSDAQ Index,
KOSDAQ,
006400.KS,
066970.KS,
003670.KS,
128940.KS,
XBI,
Korean biotech/pharma ETF,
Korean semiconductor sector,
Korean semiconductor materials/equipment